

Review Form 1.6

Journal Name:	Journal of Pharmaceutical Research International
Manuscript Number:	Ms_JPRI_83172
Title of the Manuscript:	REAL-WORLD SINGLE-CENTER EXPERIENCE WITH DIRECT-ACTING ANTIVIRALS FOR IMPROVEMENT OF THE LIVER FIBROSIS AFTER CHRONIC HEPATITIS C TREATMENT
Type of the Article	Original Research Article

General guideline for Peer Review process:

This journal's peer review policy states that **NO** manuscript should be rejected only on the basis of '**lack of Novelty**', provided the manuscript is scientifically robust and technically sound. To know the complete guideline for Peer Review process, reviewers are requested to visit this link:

<https://www.journaljpri.com/index.php/JPRI/editorial-policy>

PART 1: Review Comments

	Reviewer's comment	Author's comment (if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)
Compulsory REVISION comments	<ul style="list-style-type: none">- Kindly, you mentioned that the study was conducted in 2017-2018 where Sofosbuvir / Ribavirin was removed from the EASL protocol.- APRI score is not sufficiently sensitive- CTP is not calculated in patients with decompensated cirrhosis knowing that class B > 6 and C are not candidate for treatment- Even if the study is retrospective a patient consent to take the treatment is requested	
Minor REVISION comments	Language and spelling eg. Complaint is written compliant	
Optional/General comments		

PART 2:

	Reviewer's comment	Author's comment (if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)
Are there ethical issues in this manuscript?	<i>(If yes, Kindly please write down the ethical issues here in details)</i>	

Reviewer Details:

Name:	Mai Mehrez
Department, University & Country	Armed Forces College of Medicine, Egypt